Amended Report of Foreign Issuer (6-k/a)
21 Fevereiro 2020 - 3:44PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: February 20, 2020
Commission File Number: 001-38844
GENFIT S.A.
(Translation of registrant’s name into English)
Parc Eurasanté
885, avenue Eugène Avinée
59120 Loos, France
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ☐
EXPLANATORY NOTE
This report on Form 6-K/A amends GENFIT (the “Company”)’s
report on Form 6-K furnished to the U.S. Securities and Exchange Commission on February 20, 2020 (the ”February 20, 2020
6-K”) to clarify that the RESOLVE-IT Phase 3 trial evaluating elafibranor in NASH remains blinded at this time. The revised
Exhibit 99.2 amends and replaces Exhibit 99.1 of the February 20, 2020 6-K. Other than mentioned above, no part of the Form
6-K furnished on February 20, 2020 is being amended.
EXHIBIT LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
GENFIT S.A.
|
|
|
|
|
Date: February 21, 2020
|
|
|
|
By:
|
|
/s/ Pascal PRIGENT
|
|
|
|
|
|
|
Name: Pascal PRIGENT
|
|
|
|
|
|
|
Title: Chief Executive Officer
|
Genfit (NASDAQ:GNFT)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Genfit (NASDAQ:GNFT)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024